Benchtop NMR Spectroscopy for Assessment of Clinical Human Pathologies (BRANCH-P STUDY) (BRANCH-P)
Preclinical Drug Discovery Informed by Public Health: Initiating a Step-Change in the Development of New Human Models
調査の概要
状態
詳細な説明
The research project aims to gauge the efficacy of benchtop Nuclear Magnetic Resonance devices in a primary health care setting. The study design and methodology is as follows:
Typically, before a patient attends their routine standard of care blood test, they will speak with their local General Practitioner (GP) or a Registered Nurse (RN). At these visits, the medical professional will gauge the interest of the patient and test if they are eligible. If the patient is interested in becoming involved with research, and they are eligible for the study, they will be given a 'Study Information and Informed Consent Form' to read before their next visit. This allows for ample time to become fully informed on what the study entails, as well as to ask any questions they may have.
The 'Study Information and Informed Consent Form' document contains all information detailing: the purpose of the study, the significance of the research, and the patient's right to withdraw at any time (as in accordance with General Data Protection Regulations [GDPR] 2018), potential risks and benefits of taking part in the study and who to contact if the patient had any further questions to be asked.
At the patient's routine standard of care visit, they will present their signed and dated consent form to the medical professional taking the biological samples. If the patient loses their consent form before this visit, they will be given another to complete in full before any residual biological samples are taken. This will be counter-signed by the medical professional present at their visit. The patient will then be anonymised by being given a unique identifier in the form of a barcode. This barcode will be applied to the consent form, and the form will act as a linking document. The patient will only be referred by their unique identifier for the remainder of the study. This anonymisation of identifiable patient information (such as name, Date of Birth [DoB], etc.) extends to any data produced by analysing the patient's samples. The patient will keep a copy of the consent form for their own records, whilst the original document will be held by the research team to be stored on-site behind several layers of security. A copy of the consent form will also be uploaded onto the patients SystmOne profile. SystmOne is a clinical computer system used by medical professionals to log patient visits, review tests results and upload any new relevant data.
After sample collection, no further actions are required of the patient for the remainder of the study. The patient will be given a debriefing document thanking them for their contribution. Within this document there are contact details of the researchers involved and other contact telephone numbers to a variety of organisations and helplines specialising in emotional support, if the patient feels in any way affected by the study. The patient will also be offered the opportunity to be given a copy of their bio fluid spectral data should they be interested in this. This will be accompanied by explanatory notes.
The biological samples collected from the patient will go to two different locations: samples taken as part of the patient's routine standard of care will go to a local diagnostics lab where they will be tested on a variety of metrics. Residual biological samples will be processed and tested at the local Willows Health Near Patient Testing laboratory, before being frozen at -80oC.
The test results provided by the diagnostics lab will be uploaded to the patient's SystmOne account, where they will be scribed and used for the study, as outlined in the 'Study Information and Informed Consent Form' document. Results gathered from the Willows Health Near Patient Testing laboratory will also be uploaded to the patients SystmOne account and stored for later use within the study. The combination of these two sets of data will form the Near Patient Testing data set.
The residual biological samples frozen at Willows Health will then be transferred in batch format to Nottingham Trent University's (NTU's) benchtop Nuclear Magnetic Resonance device. They will then be thawed, prepared further and analysed using the benchtop Nuclear Magnetic Resonance device. The resultant spectra will be stored on the password protected device to form the benchtop Nuclear Magnetic Resonance data set. With both sets of data gathered (Near Patient Testing suite and benchtop Nuclear Magnetic Resonance spectra), a machine learning algorithm will cross-compare the data sets to 'teach' a program to 'read' the benchtop Nuclear Magnetic Resonance spectra and output data in the form of Near Patient Testing machines.
On average, ~42 patients attend the Willows Health Medical Centre for routine standard of care visits per week in which biological samples are collected for pathology lab testing. This equates to ~168 samples per month. With the sample collection window planned to take a year, this calculates to ~2016 potential participants being involved within the study. This is an estimated maximum, as not all patients who come for their annual review may not consent to the research study. Additionally, some religious events and holidays may limit the uptake of potential participants, for example: during Ramadan, although it is not strictly prohibited, blood tests may be avoided due to the weakening effect it may have. This, in conjunction with fasting, may dissuade potential participants from joining the study.
Given the substantial volumes of data required to 'train' software when utilising machine learning algorithms, the sample size needs to be large. This is imperative to produce accurate and reliable results from training and test sets for machine learning algorithms.
This research will result in several advantages for both clinical care and patients. For instance, efficient and rapid analysis of biological fluids will help to overcome the limitations associated with diagnosis of a variety of diseases such diabetes, chronic kidney disease, cancer and any other conditions that might go asymptomatic in the early stages. This work has the potential to pave the way for new clinical pathological techniques to support the early diagnosis of diseases.
研究の種類
入学 (予想される)
連絡先と場所
研究連絡先
- 名前:Philippe B Wilson
- 電話番号:+44 07777688519
- メール:philippe.wilson@ntu.ac.uk
研究連絡先のバックアップ
- 名前:Daniel JS Wolski
- 電話番号:+44 07776415044
- メール:daniel.wolski@nhs.net
研究場所
-
-
Leicestershire
-
Leicester、Leicestershire、イギリス、LE5 4LJ
- Willows Medical Centre
-
コンタクト:
- Daniel JS Wolski
- 電話番号:+44 07776415044
- メール:daniel.wolski@nhs.net
-
コンタクト:
- Imran Kapasi
- 電話番号:+44 07428589207
- メール:imran.kapasi@nhs.net
-
主任研究者:
- Philippe B Wilson
-
主任研究者:
- Rishabh Prasad
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
All participants must satisfy ALL the following criteria at study entry:
- A male or female aged equal to or greater than 18 years of age.
- Participants who, in the opinion of the investigator, can and will comply with requirements of the study procedures (e.g. Attend routine standard of care testing clinics, agree to share routine standard of care test results for the purposes of research, etc.).
- Participants who are able to provide written informed consent.
Exclusion Criteria:
If any of the exclusion criterion applies, the participant must not be included in the study:
- Participants who are unable to provide consent due to incapacity.
研究計画
研究はどのように設計されていますか?
デザインの詳細
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Signal to Noise
時間枠:PhD study duration (Final Submission Date: 22 June 2025)
|
An >0.97 (or 97%) area under the receiver operating characteristic (AUROC) of benchtop Nuclear Magnetic Resonance versus current Point of Care (POC) testing sensitivity/specificity in conditional classification of samples.
|
PhD study duration (Final Submission Date: 22 June 2025)
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Philippe B Wilson、Professor at Nottingham Trent University
- 主任研究者:Rishabh Prasad、Partner at Willows Health
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (予想される)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 精神障害
- 化学誘発性疾患
- 消化器系疾患
- 病理学的プロセス
- 代謝疾患
- 脳疾患
- 中枢神経系疾患
- 神経系疾患
- アルコール関連障害
- 物質関連障害
- 気道感染症
- 気道疾患
- 肺疾患
- 泌尿器疾患
- 炎症
- 神経認知障害
- 疾患の属性
- 兆候と症状、消化器
- 消化器疾患
- 気管支疾患
- 腎不全
- 筋骨格疾患
- 結合組織病
- 胃腸炎
- 神経変性疾患
- 腸の病気
- 皮膚病、感染症
- 肺疾患、閉塞性
- 過食症
- 骨の病気
- 脂質代謝異常症
- 認知症
- タウオパシー
- 化膿
- 高脂血症
- 脂質異常症
- 骨疾患、代謝
- 盲腸疾患
- 腹腔内感染症
- アルコール誘発性障害
- 肝疾患
- 心臓疾患
- 心血管疾患
- 腎臓病
- 腎不全、慢性
- 消化不良
- 感染症
- 伝染病
- 過食症
- アルツハイマー病
- 蜂窩織炎
- 高コレステロール血症
- 骨粗鬆症
- 虫垂炎
- 気管支炎
- 肝臓病、アルコール依存症
その他の研究ID番号
- CRT00442
- 315046 (その他の識別子:IRAS Application Project ID)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。